AMLN Amylin Pharmaceuticals, Inc. (MM)

SAN DIEGO, Jan. 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) announced that, effective today, it has been added to the NASDAQ-100 Index(R), which is composed of the 100 largest non-financial stocks on The NASDAQ Stock Market(R) based on market capitalization and eligibility criteria. "We are pleased to be included on the NASDAQ-100 Index and listed among the top companies in the world," said Ginger L. Graham, President and CEO of Amylin Pharmaceuticals, Inc. "It is particularly meaningful following our company's successful transition to a fully commercial organization in 2005 and the market adoption of our first-in-class diabetes products BYETTA(R) and SYMLIN(R)." Amylin has a market capitalization of $4.4 billion. About the NASDAQ-100 Index The NASDAQ-100 Index, launched in January 1985, is one of the most widely followed benchmarks in the world. The NASDAQ-100 Index Tracking Stock represents ownership in the NASDAQ-100 Trust. The Trust holds a portfolio of equity securities that compose the NASDAQ-100 Index and aims to provide investment results that generally correspond with the performance of the Index. NASDAQ(R) is the largest electronic screen-based equity securities market in the United States. With approximately 3,200 companies, it lists more companies and, on average, trades more shares per day than any other U.S. market. It is home to companies that are leaders across all areas of business including technology, retail, communications, financial services, transportation, media and biotechnology. About Amylin Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin is located in San Diego, California with over 1000 employees nationwide. Further information on Amylin Pharmaceuticals and its pipeline in metabolism is available at http://www.amylin.com/ . This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. The Company's actual results could differ materially from those discussed due to a number of risks and uncertainties, including risks that BYETTA and/or SYMLIN may not prove to be important new therapeutic options or may be affected by unexpected new data or technical issues, and risks and uncertainties inherent in the drug discovery and development process. Commercial and government reimbursement and pricing decisions, the pace of market acceptance and any issues related to manufacturing and supply may also affect the potential for BYETTA and/or SYMLIN. These and additional risks and uncertainties are described more fully in the Company's most recently filed SEC documents, including its Form 10-Qs. Amylin undertakes no duty to update these forward-looking statements. DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Mark Foletta, VP, Finance and CFO, Amylin Pharmaceuticals, Inc., +1-858-552-2200 Web site: http://www.amylin.com/

Copyright